Loading clinical trials...
Loading clinical trials...
The RAVE (Rubeosis Anit-VEgf) Trial, Utilizes Monthly Intravitreal Bevazizumab (Avastin) Injections for 12 Months to See if Total VEGF Blockade Will Prevent Neovascular Glaucoma and Eliminate the Need for Panretinal Photocoagulation in Patients With Ischemic Central Retinal Vein Occlusion
Conditions
Interventions
bevacizumab
Start Date
November 1, 2006
Primary Completion Date
October 1, 2011
Completion Date
November 1, 2011
Last Updated
November 29, 2011
NCT04354545
NCT07298356
NCT07396441
NCT06979752
NCT07390890
NCT07145073
Lead Sponsor
Instituto de Olhos de Goiania
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions